Investigational Drug Information for Anamorelin

What is the drug development status for Anamorelin?

Anamorelin is an investigational drug.

There have been 11 clinical trials for Anamorelin. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1^st 2011.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Cachexia. The leading clinical trial sponsors are Helsinn Therapeutics (U.S.), Inc, Helsinn Healthcare SA, and National Cancer Institute (NCI).

Summary for Anamorelin

US Patents	0
International Patents	0
US Patent Applications	149
WIPO Patent Applications	54
Japanese Patent Applications	16
Clinical Trial Progress	Phase 3 (2011-07-01)
Vendors	44

Recent Clinical Trials for Anamorelin

Title	Sponsor	Phase
Anamorelin Study for Advanced Pancreatic Cancer	Helsinn Healthcare SA	Phase 2
Anamorelin Study for Advanced Pancreatic Cancer	Quartesian LLC	Phase 2
Anamorelin Study for Advanced Pancreatic Cancer	Lahey Clinic	Phase 2

See all Anamorelin clinical trials

Clinical Trial Summary for Anamorelin

Top disease conditions for Anamorelin

Top clinical trial sponsors for Anamorelin

See all Anamorelin clinical trials

US Patents for Anamorelin

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration

Anamorelin Development Update and Market Projection

Last updated: February 20, 2026

What is the current status of Anamorelin’s development?

Anamorelin is a selective ghrelin receptor agonist primarily developed for treating cancer cachexia. Its development has experienced multiple phases with a focus on efficacy in weight gain and appetite stimulation.

• Phase 3 trials were conducted by Ono Pharmaceutical in Japan, assessing efficacy in non-small cell lung cancer (NSCLC) patients with cachexia.
• The drug received regulatory approval in Japan in 2018 for cancer anorexia-cachexia, but it has not gained approval in the United States or Europe.
• Trials outside Japan faced challenges, including mixed efficacy data and regulatory hurdles. The Phase 3 ROMANA trials demonstrated some benefit in weight gain but failed to show significant improvements in overall survival.

What are the regulatory and clinical milestones?

Date	Event	Region	Details
2018	Approved in Japan	Japan	Authorized as a treatment for cancer cachexia
2019-2020	Clinical trial assessments	Global	Phase 3 ROMANA trials conducted in NSCLC patients
2021	UN approval application rejected	U.S./Europe	No submission for approval outside Japan
2022-2023	Ongoing or completed market evaluations	Japan	Efforts to expand indications or develop formulations

What are the competitive landscape and key challenges?

• Existing drugs targeting cachexia (e.g., megastrol acetate, corticosteroids) have limited efficacy.
• No drug has gained widespread approval for cachexia treatment across major markets.
• Anamorelin’s efficacy benefits are primarily seen in weight and appetite improvement, but impacts on survival remain unsubstantiated.
• Regulatory divergence limits global commercialization; Japan remains the primary market.

What is the market outlook for Anamorelin?

Market size and growth

• The global cachexia treatment market was valued at approximately USD 250 million in 2022 [1].
• Expected CAGR is roughly 6% from 2023 to 2030, driven by increasing cancer prevalence and unmet medical needs [2].

Key regional dynamics

• Japan remains the primary market due to regulatory approval and clinical acceptance.
• U.S. and European markets are limited; potential future approvals depend on new efficacy data or expanded indications.
• Oncology supportive care markets expand as awareness of cachexia impacts grows.

Revenue projections (2023-2030)

Year	Estimated Revenue	Notes
2023	USD 50 million	Primarily Japan sales, limited global access
2025	USD 150 million	Expansion into additional indications or markets if regulatory hurdles ease
2030	USD 300 million	Potential global penetration assuming regulatory approval in major markets

What are the key factors influencing market success?

• Efficacy in improving survival and quality of life remains a critical unmet need.
• Regulatory approval in non-Japanese markets requires compelling survival data and safety profiles.
• Partnership opportunities may accelerate global commercialization.
• Competitive differentiation depends on demonstrating better outcomes than existing medications.

Key Takeaways

Anamorelin shows promise as a treatment for cancer cachexia, particularly in Japan, where regulatory approval was granted. Its global market potential hinges on securing additional efficacy data and regulatory acceptance outside Japan. The market is expected to grow steadily, supported by rising cancer prevalence and increasing recognition of cachexia as a critical supportive care area. Commercial success depends on expanding indications, achieving regulatory milestones in key regions, and demonstrating clinical benefit in larger, more definitive trials.

FAQs

1. Will Anamorelin receive approval outside Japan?
   The likelihood depends on positive outcomes from additional trials demonstrating survival benefits and safety in diverse populations.

2. What are the main safety concerns?
   Possible concerns include metabolic effects, cardiovascular risks, and adverse events typical of ghrelin receptor agonists.

3. Are there competing drugs in development?
   Few drugs specifically target cachexia; most are supportive care drugs with limited efficacy, meaning Anamorelin has a niche if approved broadly.

4. Is there potential for expansion into other indications?
   Yes, conditions involving weight loss and appetite loss, such as HIV/AIDS and aged care, are potential areas.

5. What strategic options exist for Anamorelin’s commercialization?
   Partnerships with global pharmaceutical companies, licensing agreements, or pursuing additional clinical data could help expand its market presence.

References

[1] Grand View Research. (2022). Cachexia Treatment Market Size, Share & Trends Analysis Report.
[2] MarketsandMarkets. (2022). Oncology Supportive Care Market Forecast.